Published in Antimicrob Agents Chemother on March 01, 2002
Combination antifungal therapy. Antimicrob Agents Chemother (2004) 3.49
Combination treatment of invasive fungal infections. Clin Microbiol Rev (2005) 1.59
In vitro interaction of flucytosine combined with amphotericin B or fluconazole against thirty-five yeast isolates determined by both the fractional inhibitory concentration index and the response surface approach. Antimicrob Agents Chemother (2002) 1.23
Extra copies of the Aspergillus fumigatus squalene epoxidase gene confer resistance to terbinafine: genetic approach to studying gene dose-dependent resistance to antifungals in A. fumigatus. Antimicrob Agents Chemother (2004) 1.01
In vitro synergistic interaction between amphotericin B and pentamidine against Scedosporium prolificans. Antimicrob Agents Chemother (2002) 0.99
Potent synergistic in vitro interaction between nonantimicrobial membrane-active compounds and itraconazole against clinical isolates of Aspergillus fumigatus resistant to itraconazole. Antimicrob Agents Chemother (2004) 0.98
In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata. Antimicrob Agents Chemother (2004) 0.88
In vitro interactions between amphotericin B, itraconazole, and flucytosine against 21 clinical Aspergillus isolates determined by two drug interaction models. Antimicrob Agents Chemother (2004) 0.88
Triclosan antagonizes fluconazole activity against Candida albicans. J Dent Res (2011) 0.76
In vitro effects of spectinomycin and ceftriaxone alone or in combination with other antibiotics against Chlamydia trachomatis. Antimicrob Agents Chemother (2005) 0.75
In vitro additive interaction between ketoconazole and antimony against intramacrophage Leishmania (Leishmania) amazonensis amastigotes. PLoS One (2017) 0.75
Novel Antifungal Activity for the Lectin Scytovirin: Inhibition of Cryptococcus neoformans and Cryptococcus gattii. Front Microbiol (2017) 0.75
A method for testing for synergy with any number of agents. J Infect Dis (1978) 9.52
The search for synergy: a critical review from a response surface perspective. Pharmacol Rev (1995) 8.24
Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis (2000) 5.53
Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev (1999) 5.51
Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect (1996) 4.26
Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test. Antimicrob Agents Chemother (1996) 3.40
In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diagn Microbiol Infect Dis (1992) 2.41
Activities of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii. Antimicrob Agents Chemother (1995) 2.12
Antifungal drug resistance in Aspergillus. J Infect (2000) 2.01
In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. Antimicrob Agents Chemother (1995) 1.77
Comparison of NCCLS and 3-(4,5-dimethyl-2-Thiazyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method. J Clin Microbiol (2000) 1.76
Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species. Med Mycol (2001) 1.35
Invasive aspergillosis in transplant recipients. Medicine (Baltimore) (1999) 1.31
Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro. Antimicrob Agents Chemother (1998) 1.31
Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro. Antimicrob Agents Chemother (1997) 1.23
Interactions between triazoles and amphotericin B against Cryptococcus neoformans. Antimicrob Agents Chemother (2000) 1.23
In-vitro interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of Candida albicans. J Antimicrob Chemother (1998) 1.22
Effects of antifungal agent combinations administered simultaneously and sequentially against Aspergillus fumigatus. Antimicrob Agents Chemother (1994) 1.09
Practice guidelines for the treatment of tuberculosis. Clin Infect Dis (2000) 1.03
Successful treatment of fluconazole-resistant oropharyngeal candidiasis by a combination of fluconazole and terbinafine. Clin Diagn Lab Immunol (1999) 0.90
Mechanism for synergism between sulphonamides and trimethoprim clarified. J Pharm Pharmacol (1996) 0.78
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect (2012) 4.56
A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother (2007) 3.54
Candida dubliniensis candidemia in patients with chemotherapy-induced neutropenia and bone marrow transplantation. Emerg Infect Dis (1999) 2.96
General primer-mediated PCR for detection of Aspergillus species. J Clin Microbiol (1994) 2.81
Comparison of three commercially available amplification assays, AMP CT, LCx, and COBAS AMPLICOR, for detection of Chlamydia trachomatis in first-void urine. J Clin Microbiol (1997) 2.71
Nasal carriage of Staphylococcus aureus as a major risk factor for wound infections after cardiac surgery. J Infect Dis (1995) 2.69
EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect (2011) 2.65
[New developments in antifungal therapy: fluconazole, itraconazole, voriconazole, caspofungin]. Ned Tijdschr Geneeskd (2004) 2.55
Colorimetric assay for antifungal susceptibility testing of Aspergillus species. J Clin Microbiol (2001) 2.53
Specificity of a sandwich enzyme-linked immunosorbent assay for detecting Aspergillus galactomannan. J Clin Microbiol (1997) 2.53
Performance of a nonisotopic DNA probe for detection of Chlamydia trachomatis in urogenital specimens. J Clin Microbiol (1991) 2.21
Aspergillus species identification in the clinical setting. Stud Mycol (2007) 1.81
Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin Microbiol Infect (2003) 1.79
Comparison of NCCLS and 3-(4,5-dimethyl-2-Thiazyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method. J Clin Microbiol (2000) 1.76
Involvement of CD14 and toll-like receptors in activation of human monocytes by Aspergillus fumigatus hyphae. Infect Immun (2001) 1.75
Reduction of surgical-site infections in cardiothoracic surgery by elimination of nasal carriage of Staphylococcus aureus. Infect Control Hosp Epidemiol (1996) 1.72
Analysis of growth characteristics of filamentous fungi in different nutrient media. J Clin Microbiol (2001) 1.68
Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus. Emerg Infect Dis (2015) 1.61
In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans. Antimicrob Agents Chemother (2000) 1.61
Susceptibility to various antimicrobial agents and tolerance to methicillin of Staphylococcus aureus isolates from cystic fibrosis patients. Eur J Clin Microbiol Infect Dis (1991) 1.57
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect (2012) 1.55
International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J Clin Microbiol (2005) 1.55
Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. Antimicrob Agents Chemother (1997) 1.53
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect (2012) 1.48
Evaluation of Clearview and Magic Lite tests, polymerase chain reaction, and cell culture for detection of Chlamydia trachomatis in urogenital specimens. J Clin Microbiol (1993) 1.47
European Committee on Antimicrobial Susceptibility Testing (EUCAST) Technical Notes on antimicrobial susceptibility testing. Clin Microbiol Infect (2006) 1.45
Patient-to-patient spread of a single strain of Corynebacterium striatum causing infections in a surgical intensive care unit. J Clin Microbiol (1996) 1.44
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect (2012) 1.41
Prevention of respiratory failure after hydrochloric acid aspiration by intratracheal surfactant instillation in rats. Anesth Analg (1993) 1.40
[An outbreak of psittacosis at a bird-fanciers fair in the Netherlands]. Ned Tijdschr Geneeskd (2008) 1.39
ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi. Clin Microbiol Infect (2014) 1.36
Current management of fungal infections. Drugs (2001) 1.34
Liposomes with prolonged blood circulation and selective localization in Klebsiella pneumoniae-infected lung tissue. J Infect Dis (1993) 1.30
Successful treatment with voriconazole of invasive aspergillosis in chronic granulomatous disease. Am J Respir Crit Care Med (1998) 1.26
Subcutaneous phaeohyphomycotic cyst caused by Pyrenochaeta romeroi. Med Mycol (2010) 1.23
In vitro interaction of flucytosine combined with amphotericin B or fluconazole against thirty-five yeast isolates determined by both the fractional inhibitory concentration index and the response surface approach. Antimicrob Agents Chemother (2002) 1.23
Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for Candida spp.: a collaborative study. J Clin Microbiol (2005) 1.20
Influence of pulmonary surfactant on in vitro bactericidal activities of amoxicillin, ceftazidime, and tobramycin. Antimicrob Agents Chemother (1995) 1.20
Vancomycin population pharmacokinetics in neonates. Clin Pharmacol Ther (2000) 1.20
A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints. Infection (2009) 1.19
Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Intensive Care Med (2002) 1.18
Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios. Antimicrob Agents Chemother (2003) 1.17
Trends in invasive fungal infections, with emphasis on invasive aspergillosis. Clin Microbiol Infect (2009) 1.17
Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model. Antimicrob Agents Chemother (1997) 1.16
Interlaboratory reproducibility of a microsatellite-based typing assay for Aspergillus fumigatus through the use of allelic ladders: proof of concept. Clin Microbiol Infect (2009) 1.15
Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections. Antimicrob Agents Chemother (1997) 1.15
Use of the t > MIC to choose between different dosing regimens of beta-lactam antibiotics. J Antimicrob Chemother (2001) 1.14
Different demographic and sexual correlates for chlamydial infection and gonorrhoea in Rotterdam. Int J Epidemiol (1997) 1.14
Fungal contamination of tobacco and marijuana. JAMA (2000) 1.10
The clinical spectrum of Exophiala jeanselmei, with a case report and in vitro antifungal susceptibility of the species. Med Mycol (2010) 1.10
Oral terbinafine for treatment of pulmonary Pseudallescheria boydii infection refractory to itraconazole therapy. Eur J Clin Microbiol Infect Dis (1997) 1.10
Recovery of filamentous fungi from water in a paediatric bone marrow transplantation unit. J Hosp Infect (2001) 1.09
Epidemiological cutoff values for azoles and Aspergillus fumigatus based on a novel mathematical approach incorporating cyp51A sequence analysis. Antimicrob Agents Chemother (2012) 1.09
Faucet aerators: A source of patient colonization with Stenotrophomonas maltophilia. Am J Infect Control (1999) 1.08
Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions. Clin Pharmacokinet (1998) 1.06
Decreased ciprofloxacin susceptibility in Salmonella Typhi and Paratyphi infections in ill-returned travellers: the impact on clinical outcome and future treatment options. Eur J Clin Microbiol Infect Dis (2013) 1.05
[Continuous intravenous home treatment of airway infections using ceftazidime administration via portable pump in patients with cystic fibrosis; a multicenter study]. Ned Tijdschr Geneeskd (1993) 1.04
Use of pharmacodynamic parameters to predict efficacy of combination therapy by using fractional inhibitory concentration kinetics. Antimicrob Agents Chemother (1998) 1.02
Combination chemotherapy for the treatment of invasive infections by Scedosporium prolificans. Clin Microbiol Infect (2000) 1.02
Efficacy and pharmacodynamics of flucytosine monotherapy in a nonneutropenic murine model of invasive aspergillosis. Antimicrob Agents Chemother (2005) 1.01
Effect of pH on the in vitro activities of amphotericin B, itraconazole, and flucytosine against Aspergillus isolates. Antimicrob Agents Chemother (2004) 1.00
Exogenous pulmonary surfactant as a drug delivering agent: influence of antibiotics on surfactant activity. Br J Pharmacol (1996) 0.98
Simultaneous determination of the azoles voriconazole, posaconazole, isavuconazole, itraconazole and its metabolite hydroxy-itraconazole in human plasma by reversed phase ultra-performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci (2012) 0.98
Duration and clinical relevance of postantibiotic effect in relation to the dosing interval. Antimicrob Agents Chemother (1998) 0.96
Comparison of pharmacodynamics of azithromycin and erythromycin in vitro and in vivo. Antimicrob Agents Chemother (1998) 0.96
Pulmonary surfactant as vehicle for intratracheally instilled tobramycin in mice infected with Klebsiella pneumoniae. Br J Pharmacol (1996) 0.96
Relationship between in vitro activities of amphotericin B and flucytosine and pH for clinical yeast and mold isolates. Antimicrob Agents Chemother (2005) 0.96
Improved efficacy of ciprofloxacin administered in polyethylene glycol-coated liposomes for treatment of Klebsiella pneumoniae pneumonia in rats. Antimicrob Agents Chemother (2001) 0.95
Rhinocladiella aquaspersa, proven agent of verrucous skin infection and a novel type of chromoblastomycosis. Med Mycol (2010) 0.95
Tobramycin population pharmacokinetics in neonates. Clin Pharmacol Ther (1997) 0.95
Delta APACHE II for predicting course and outcome of nosocomial Staphylococcus aureus bacteremia and its relation to host defense. J Infect Dis (1996) 0.94
Primary hepatic invasive aspergillosis with progression after rituximab therapy for a post transplantation lymphoproliferative disorder. Ann Hematol (2006) 0.94
Chlamydia antibody testing and diagnosing tubal pathology in subfertile women: an individual patient data meta-analysis. Hum Reprod Update (2011) 0.94
Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections. J Antimicrob Chemother (2002) 0.94
Exchange of Pseudomonas aeruginosa strains among cystic fibrosis siblings. Res Microbiol (1997) 0.94
In vivo efficacy of trovafloxacin against Bacteroides fragilis in mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model. Antimicrob Agents Chemother (2001) 0.93
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases. Clin Microbiol Infect (2012) 0.93
Lung overinflation without positive end-expiratory pressure promotes bacteremia after experimental Klebsiella pneumoniae inoculation. Intensive Care Med (1998) 0.93
Disseminated Rhizopus microsporus infection in a patient on oral corticosteroid treatment: a case report. Neth J Med (2009) 0.93
An adult case of oral infection with Kingella kingae. Int J Oral Maxillofac Surg (2004) 0.92